EGFR and neoplasm: The development of acquired BRAF V600E has been reported to render tumor insensitivity to EGFR-TKIs treatment (Ohashi et al., 2012; Ricordel et al., 2018; Westover et al., 2018), indicating potential clinical benefits of EGFR and BARF co-inhibition in cases with dual mutations.